Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer

Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer

Abstract Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer that presents as de novo metastatic disease in 20–30% of cases, with one-third of cases demonstrating HER2-positivity. There has been limited investigation into locoregional therapy utilization following HER2-direc...

Full description

Bibliographic Details
Main Authors: Ana C. Garrido-Castro, Meredith M. Regan, Samuel M. Niman, Faina Nakhlis, Claire Remolano, Jennifer M. Rosenbluth, Caroline Block, Laura E. Warren, Jennifer R. Bellon, Eren Yeh, Beth T. Harrison, Elizabeth Troll, Nancy U. Lin, Sara M. Tolaney, Beth Overmoyer, Filipa Lynce
Format: Article
Language:English
Published: Nature Portfolio 2023-06-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-023-00555-w

Internet

https://doi.org/10.1038/s41523-023-00555-w

Similar Items